Poor
Not Aligned
Patient Risk:
Low
Summary
None of the extracted claims are supported by the provided FDA label excerpt (DESCRIPTION only). One claim regarding equivalence/interchangeability across salts/esters is potentially misleading because the excerpt does not establish such interchangeability.
Category Scores
Accurate Statements
Unsupported Statements
Dexamethasone is also known by the alternative name dexamethasone sodium phosphate (often for injectable/ophthalmic formulations).
The provided label excerpt does not state that 'dexamethasone sodium phosphate' is an alternative name/synonym for dexamethasone or provide any equivalence statement.
Dexamethasone is also known by the alternative name dexamethasone phosphate (shorthand for the sodium phosphate form in some contexts).
The provided label excerpt does not mention 'dexamethasone phosphate' or any shorthand/equivalence to a specific salt form.
Dexamethasone is also known by the alternative name dexamethasone acetate (common for some formulations, including certain ophthalmic/otic products).
The provided label excerpt does not mention 'dexamethasone acetate' or any synonym/equivalence statement.
Dexamethasone is marketed under different brand names worldwide.
The provided label excerpt does not discuss brand names or marketing.
The exact brand name of dexamethasone depends on the manufacturer and dosage form (tablet, injection, eye/ear drops, topical).
The provided label excerpt does not address brand-name variability by manufacturer or dosage form.
Different salts/esters of dexamethasone (such as sodium phosphate vs. acetate) change the listed chemical name but not the core drug (dexamethasone).
The provided label excerpt provides a chemical designation for dexamethasone but does not state that different salts/esters are equivalent/interchangeable or that they 'change the listed chemical name but not the core drug.'
Dexamethasone is different from prednisone.
The provided label excerpt does not compare dexamethasone to prednisone.
Dexamethasone is different from prednisolone.
The provided label excerpt does not compare dexamethasone to prednisolone.
Contradictions
Important Omissions
Label-supported identification details relevant to the claims (e.g., explicit synonym/alias language for 'sodium phosphate,' 'acetate,' or any stated interchangeability across salts/esters; and any brand-name or formulation naming statements).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most claims are naming/marketing comparisons and are not supported by the provided excerpt. However, the claim about salts/esters being interchangeable without label support could be misleading for dispensing/prescribing if formulation strength/route-specific labeling differ; the provided excerpt does not establish this.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
No extracted claims are supported by the provided FDA label excerpt; one claim implies interchangeability across salts/esters without label support.
Suggested Improvement
Remove or revise unsupported synonym/brand/interchangeability claims unless supported by specific on-label language in the FDA-approved labeling; cite the exact label sections that state the relevant aliases or equivalence.